#GeneticBreakthrough
White oak’s genetic code unlocked! A deep dive into Quercus alba reveals the secrets of its resilience. Key to adapting forests. #ScienceMeetsConservation.
Safeguarding an American icon. 🌳

#GeneticBreakthrough #FutureForests
Scientists decode the DNA of one of America's most iconic trees, the white oak
Highly valued economically, ecologically and culturally, the white oak (Quercus alba) is a keystone forest species and is one of the most abundant trees across much of eastern North America. It also f...
phys.org
February 25, 2025 at 6:00 AM
Living mouse created with stem cells that predate animals: Scientists used genes from unicellular protists to reprogram mouse cells into stem cells. These cells developed into a living mouse embryo.

#StemCellResearch #LivingMouse #PrehistoricCells #GeneticBreakthrough #EarthDotCom #Earth
Living mouse created with stem cells that predate animals
Scientists used genes from unicellular protists to reprogram mouse cells into stem cells. These cells developed into a living mouse embryo.
www.earth.com
December 1, 2024 at 10:45 PM
A scalable platform for patient-derived organoids enables rapid screening of personalized ASOs for rare diseases, enhancing preclinical evaluations. #GeneticBreakthrough PMID:39843740, Nature 2025, @Nature https://doi.org/10.1038/s41586-024-08462-1 #Medsky #Pharmsky #RNA 🧪
Rapid and scalable personalized ASO screening in patient-derived organoids | Nature
Personalized antisense oligonucleotides (ASOs) have achieved positive results in the treatment of rare genetic disease1. As clinical sequencing technologies continue to advance, the ability to identify patients with rare disease harbouring pathogenic genetic variants amenable to this therapeutic strategy will probably improve. Here we describe a scalable platform for generating patient-derived cellular models and demonstrate that these personalized models can be used for preclinical evaluation of patient-specific ASOs. We describe protocols for delivery of ASOs to patient-derived organoid models and confirm reversal of disease-associated phenotypes in cardiac organoids derived from a patient with Duchenne muscular dystrophy (DMD) with a structural deletion in the gene encoding dystrophin (DMD) that is amenable to treatment with existing ASO therapeutics. Furthermore, we designed novel patient-specific ASOs for two additional patients with DMD (siblings) with a deep intronic variant in
doi.org
March 21, 2025 at 2:10 AM